HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hideki Suganami Selected Research

6- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triol

1/2021Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
1/2020Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.
11/2019Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
1/2019Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin.
1/2019Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status.
7/2018Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.
4/2018Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes.
1/2018Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.
4/2014Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
3/2014Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hideki Suganami Research Topics

Disease

12Type 2 Diabetes Mellitus (MODY)
01/2021 - 03/2014
6Hypertriglyceridemia
01/2022 - 01/2018
6Dyslipidemias (Dyslipidemia)
01/2021 - 01/2016
4Weight Loss (Weight Reduction)
01/2021 - 01/2019
4Insulin Resistance
01/2020 - 01/2018
4Drug-Related Side Effects and Adverse Reactions
06/2018 - 01/2016
3Body Weight (Weight, Body)
01/2021 - 03/2014
3Ocular Hypertension (Glaucoma, Suspect)
02/2016 - 06/2015
3Open-Angle Glaucoma (Glaucoma, Open Angle)
02/2016 - 06/2015
2Hyperlipidemias (Hyperlipidemia)
09/2018 - 05/2018
2Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
05/2018 - 01/2016
1Cardiovascular Diseases (Cardiovascular Disease)
01/2022
1Alcoholic Fatty Liver
11/2021
1Non-alcoholic Fatty Liver Disease
11/2021
1Liver Cirrhosis (Hepatic Cirrhosis)
11/2021
1Obesity
01/2020
1Diabetes Mellitus
11/2019
1Atherosclerosis
09/2018
1Albuminuria
04/2018
1Allergic Conjunctivitis (Giant Papillary Conjunctivitis)
02/2016
1Exfoliation Syndrome
02/2016
1Blepharitis
02/2016

Drug/Important Bio-Agent (IBA)

11(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA
01/2022 - 01/2018
10Glucose (Dextrose)FDA LinkGeneric
01/2021 - 03/2014
106- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
01/2021 - 03/2014
6Sodium-Glucose Transport ProteinsIBA
01/2020 - 04/2014
5Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2022 - 01/2017
5LipidsIBA
11/2021 - 01/2018
5SodiumIBA
01/2021 - 03/2014
5Sodium-Glucose Transporter 2 InhibitorsIBA
01/2021 - 03/2014
4Triglycerides (Triacylglycerol)IBA
01/2022 - 06/2018
4Peroxisome Proliferator-Activated Receptors (PPAR)IBA
11/2021 - 01/2018
3Insulin (Novolin)FDA Link
01/2020 - 01/2018
3Fenofibrate (CiL)FDA LinkGeneric
06/2018 - 01/2016
3K-115IBA
02/2016 - 06/2015
2Nonesterified Fatty Acids (NEFA)IBA
01/2020 - 01/2019
2oxidized low density lipoproteinIBA
11/2019 - 05/2018
2pitavastatin (itavastatin)FDA Link
05/2018 - 01/2016
2rho-Associated KinasesIBA
02/2016 - 06/2015
1Brain Natriuretic Peptide (Natrecor)FDA Link
01/2021
1fibroblast growth factor 21IBA
01/2021
13-Hydroxybutyric Acid (beta-Hydroxybutyric Acid)IBA
01/2020
1C-PeptideIBA
01/2020
1LDL CholesterolIBA
11/2019
1Glucagon-Like Peptide-1 ReceptorIBA
11/2019
1Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
01/2019
1CholesterolIBA
09/2018
1Glycated Serum AlbuminIBA
01/2018
1Synthetic Prostaglandins (Prostaglandin Analogues)IBA
02/2016
1TabletsIBA
01/2016
1Latanoprost (Xalatan)FDA Link
07/2015
1Timolol (Blocadren)FDA LinkGeneric
07/2015
1Hypoglycemic Agents (Hypoglycemics)IBA
04/2014
1Blood Glucose (Blood Sugar)IBA
03/2014

Therapy/Procedure

4Therapeutics
11/2021 - 02/2016
1Glycemic Control
03/2014
1Exercise Therapy (Therapy, Exercise)
03/2014